Bevacizumab and miR200c effectively reversed EMT, enhancing drug sensitivity, and were proposed as potential strategies for overcoming chemotherapy resistance in EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.